Soleno Therapeutics (SLNO) Receivables (2013 - 2026)

Soleno Therapeutics (SLNO) reported Receivables of $47.1 million for Q1 2026, up 67.11% quarter-over-quarter from $28.2 million in Q4 2025.

Soleno Therapeutics (SLNO) Receivables (2013 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 8 years of Receivables data on file, last reported at $47.1 million in Q1 2026.

Receivables for Q1 2026 came in at $47.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $47.1 million (changed N/A YoY), and the FY2025 annual result was $28.2 million, changed N/A from the prior year.
Receivables advanced to $47.1 million in Q1 2026 per SLNO's latest filing, from $28.2 million in the prior quarter.
Over five years, Receivables peaked at $47.1 million in Q1 2026 and troughed at $24.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	13.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.00 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Soleno Therapeutics	2.76 Bn	2.51 Bn	93.41 Mn	47.14 Mn

Download Data